Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Insider Buys $99,600.00 in Stock

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) insider David Young acquired 124,500 shares of the company’s stock in a transaction dated Monday, January 27th. The shares were bought at an average price of $0.80 per share, for a total transaction of $99,600.00. Following the acquisition, the insider now directly owns 205,405 shares of the company’s stock, valued at approximately $164,324. This trade represents a 153.88 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Processa Pharmaceuticals Trading Up 0.6 %

Processa Pharmaceuticals stock traded up $0.00 during mid-day trading on Wednesday, hitting $0.59. The company had a trading volume of 2,168,887 shares, compared to its average volume of 178,404. The stock’s 50 day moving average price is $0.93 and its two-hundred day moving average price is $1.24. Processa Pharmaceuticals, Inc. has a 12 month low of $0.47 and a 12 month high of $3.31. The company has a market capitalization of $1.94 million, a PE ratio of -0.17 and a beta of 0.62.

Processa Pharmaceuticals (NASDAQ:PCSA) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.03). Equities research analysts anticipate that Processa Pharmaceuticals, Inc. will post -4.05 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Processa Pharmaceuticals in a research note on Thursday, December 5th.

About Processa Pharmaceuticals

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.